AGENDA ALABAMA MEDICAID AGENCY PHARMACY AND THERAPEUTICS (P&T) COMMITTEE

May 8, 2024 1:00 p.m. – 3:00 p.m.

1.	Opening remarks
2.	Approval of February 7, 2024 P&T Committee Meeting minutes
3.	Pharmacy program update
4.	Oral presentations by manufacturers/manufacturers' representatives
	(prior to each respective class review)
5.	
	• Skin and Mucus Membrane Immunomodulators – AHFS 849200 (current brands to be included: Bimzelx®, Adbry®, Dupixent®, Ilumya®, Siliq®, Skyrizi®, Sotyktu®, Spevigo®, Stelara®, Taltz®, Tremfya® only)
6.	Pharmacotherapy class re-reviewsUMass Clinical Pharmacy Services
	Central Alpha-Agonists – AHFS 240816
	• Direct Vasodilators – AHFS 240820
	 Peripheral Adrenergic Inhibitors – AHFS 240832
	Hypotensive Agents, Miscellaneous – AHFS 240892
	Alpha-Adrenergic Blocking Agents – AHFS 242000
	Beta-Adrenergic Blocking Agents – AHFS 242400
	• Dihydropyridines – AHFS 242808
	 Calcium-Channel Blocking Agents, Miscellaneous – AHFS 242892
	Angiotensin-Converting Enzyme Inhibitors – AHFS 243204
	 Angiotensin II Receptor Antagonists – AHFS 243208
	Mineralocorticoid (Aldosterone) Receptor Antagonists – AHFS 243220
	Renin Inhibitors – AHFS 243240
	• Loop Diuretics – AHFS 402808
	Potassium-Sparing Diuretics – AHFS 402816
	• Thiazide Diuretics – AHFS 402810
	Thiazide Diuretics – AHFS 402820 Thiazide-Like Diuretics – AHFS 402824
	Vasopressin Antagonists – AHFS 402828
	 Vasopiessiii Altagoliists – AHFS 402828 Diuretics, Miscellaneous – AHFS 402892
	 Alzheimer's Agents Parasympathomimetic (Cholinergic) Agents – AHFS Class 120400 (current)
	brands to be included: Adlarity®, Aricept®, and Exelon® only)
	o Central Nervous System Agents, Miscellaneous – AHFS Class 289200
	(current brands to be included: Aduhelm [®] , Leqembi [®] , Namenda [®] , Namenda XR [®] , and Namzaric [®] only)
7.	New business
8.	Results of voting announced
9.	Next meeting dates
	• August 21, 2024
	• November 6, 2024
10.	Adjourn